Biotech – Crystal Equity Research

Context Therapeutics: Undervalued Cancer Fighter

Post author:Crystal Equity Research
Post published:June 3, 2025
Post category:Biotech

Portfolio of three novel immunological therapies based on bispecific T-cell engager technology, each with differentiating performance against multiple cancersEnrollment initiated in first half 2025 for Phase I clinical trials for…

Clearmind Medicine: Exploring a Pathway out of Alcohol Abuse

Post author:Crystal Equity Research
Post published:February 9, 2025
Post category:Biotech
Post comments:0 Comments

Clearmind Medicine (CMND) is a clinical stage pharmaceutical company with the promising CMND-100 candidate at the front end of its pipeline. CMND-100 is based on the psychoactive compound MEAI, shorthand for the synthetic molecule…